Long Haul COVID- Explained Based on Current Information, Part 1. A Multi Part Report, Which Will End With the Why of Ozone Therapy
#8 2023 The Rowen Premium Report
Dear Subscriber,
I have been repeatedly asked to write and update on ozone therapy, and to cover long haul COVID. Seeing the carnage that long haul, and vaccine injury is causing, I decided that it is time.
I will be writing a multipart piece on these subjects, first covering the COVID situation, and finally how ozone therapy may be an excellent therapy for COVID related issues.
You all know of COVID. It would be rather impossible living through the past 3 years not to be aware both of the infection and the vaccine that was essentially forced upon the population.
COVID was first thought to be a respiratory virus, and it had a significant mortality rate due to respiratory compromise. However, we learned that COVID was a systemic infection and attacked multiple organs, causing dysfunction. In particular, it attached to, and enters cells via an angiotensin receptor, present on many cells, and particularly in the vascular endothelium. Hence, the virus has the propensity to damage the delicate inner lining of your blood vessels, compromising your circulation anywhere, everywhere, all at once, inducing clots, and organ dysfunction. Hence, for those whose disease so affected their bodies, they could die from respiratory failure, of course, but also of a wide variety of body disturbances.
In most infectious disease recoveries, your body can clear the pathogen, then repair the damage. True, there are some pathogens that can linger and cause long term problems. For example, CMV, EBV, and other viruses are well known to cause chronic illness. We know that there are many causes of stealth infection, such as Lyme, Babesia, and so many others. The immune system fails to clear the body of the pathogens, or, at the least, keep them in full check.
So now we come to COVID virus. I’ll not address the likelihood that this was a created bioweapon. We’ll keep it medical here.